A AB BS S T TR RA AC CT T O Ob b j je ec c t ti i v ve e: : We in ves ti ga ted the ef fi cacy and sa fety of ser tra li ne in the tre at ment of dep res si on in pa ti ents with Par kin son's di se a se (PD) wit ho ut mo tor os cil la ti ons. Ser tra li ne has less po ten ti al for phar ma co ki ne tic drug in te rac ti ons than ot her an ti dep res sants and this fe a tu re ensu res an to le ra bi lity pro fi le es pe ci ally in the el derly. M Ma a t te e r ri i a al l a an nd d M Me et t h ho od ds s: : Six te en pa ti ents with PD who we re di ag no sed with ma jor dep res si on ac cor ding to DSM-IV cri te ri a we re inc lu ded in this open-la bel tri al for 8th we eks. An ti-par kin so ni an me di ca ti ons ha ve not be en mo di fi ed throug ho ut the study pe ri od. Ini ti al ser tra li ne do se was 25 mg for the first we ek and then in cra sed to 50 mg gi ven every mor ning. For as sess ment of dep res si on, Beck Dep res si on In ventory (BDI) and Ha mil ton Dep res si on Ra ting Sca le (HAM-D) we re used and Uni fi ed Par kin son's Di se a se Ra ting Sca le (UPDRS) and Ho ehn-Yahr Sca le we re used for par kin so nism. R Re e s su ul lt ts s: : BDI and HAM-D sco res dec re a sed sig ni fi cantly (p= 0.000) and cli ni cal glo bal as sess ment of ef fi cacy re ve a led "go o d" or "ex cel len t" res pon ses in all pa ti ents. Me an par kin so ni an di sa bi lity, as as sessed by the Uni fi ed Par kin son's Di se a se Ra ting Sca le (UPDRS) and Ho ehn and Yahr Sta ge sca les, re ma i ned unc han ged thro ug ho ut the study in the gro up as a who le. C Co on nc c l lu u s si i o on n: : Alt ho ugh these pre li mi nary re sults ne ed to be con fir med in lar ge pla ce bo-con trol led tri als, the re sults of the pre sent study sug gest that ser tra li ne do es not wor sen mo tor per for man ce and may be use ful in the tre at ment of dep res si on in PD.
t is well known that physi cal di sa bi lity has a cle ar ef fect on he alth-re la ted qu a lity of li fe in pa ti ents with Par kin son's di se a se (PD) and has be en con sis tently the fo cus of the ra pe u tic re se arch. Ho we ver, it is be co ming in cre a singly ap pa rent that psychi at ric di sor ders ha ve a con si de rab le im pact on the qu a lity of li fe. Pre vi o us stu di es ha ve shown that 40% of re duc ti on in the qu a lity of li fe in PD can be exp la i ned by dep res si on. 1 Dep res si on is one of the most com mon psychi at ric dis tur ban ces in PD, with an ave ra ge pre va len ce of abo ut 40% (ran ge, 25%-70%). [1] [2] [3] [4] Dep res si on is par ti cu larly im por tant in the se pa ti ents be ca u se, in ad di ti on to the per so nal suf fering, it is as so ci a ted with fas ter prog res si on of physi cal symptoms, 5 gre a ter dec li ne in cog ni ti ve skills, 6 and inabi lity to ca re for one self. 7 Dif fe rent cri te ri a and scre e ning to ols ha ve be en used when di ag nosing dep res si on in pa ti ents with PD, re sul ting in vari ab le es ti ma tes of the oc cur ren ce of this con di ti on. Addotionally, cli ni cal over lap ping bet we en the signs and symptoms of dep res si on and so me of those of PD (e.g. fa ti gu e, slow ness) ca u ses the dis crepancy. Se ve ral stu di es ha ve fa i led to find a cle ar as so ci a ti on bet we en the se ve rity of dep res si on and mo tor di sa bi lity. Dep res si on may pre ce de or oc cur si mul ta ne o usly with cog ni ti ve im pa ir ment and in 25% of PD pa ti ents, and it pre ce des the on set of mo tor symptoms. 8 Alt ho ugh func ti o nal im pa ir ment, as well as soci o lo gi cal and psycho lo gi cal fac tors, has an inf luen ce on the mo od in PD, so me evi den ce suggests that or ga nic fac tors in vol ved in the eti o pat ho ge nene sis of dep res si on in PD. No re pi nep hri ne and sero to nin de fi cits ha ve be en imp li ca ted in the ne u roc he mi cal ba sis of this di sor der.
De ge ne ra ti on has be en re por ted in the me solim bic system, teg men tal ven tral are a, lo cus co e rule us, and se ro to ner gic nuc le us. Dep res si on in PD has be en as so ci a ted with lo wer le vels of 5-HI I A (5-hydroxy-in do la ce tic acid) in ce reb ros pi nal flu id, 9, 10 me sen cep ha lic hypo e co ge ni city, 11 and fron to me dial hypo me ta bo lism in 18-F-glu co se PET scan. 12, 13 Addionalty, dec re a se of do pa mi ne in PD may contri bu te to in cre a sed risk of dep res si on, but do pami ner gic agents alo ne do not al le vi a te the dep ressi ve symptoms.
14 Le vo do pa has no ef fect on depres si on alt ho ugh it im pro ves mo tor symptoms. Therefore, it is not pos sib le to sug gest that at tempts to es tab lish an as so ci a ti on bet we en dep res si on and al te red do pa mi ne me ta bo lism in PD ha ve yi el ded sa tis fac tory re sults.
Tricy clic an ti dep res sants (TCAs) and se lec ti ve se ro to nin re-up ta ke in hi bi tors (SSRIs) are the mains tays of tre at ment of dep res si on in pa ti ents with PD. Se ve ral stu di es de mons tra ted the use ful ness of TCAs in the tre at ment of dep res si on in PD, but they ha ve a re la ti vely high in ci den ce of se ri o us anti-cho li ner gic si de ef fects, es pe ci ally in the el derly po pu la ti on and are con tra in di ca ted in pa ti ents who ex pe ri en ced he art blocks or con duc ti on ab nor mali ti es, se ve re arrhy thmi as or a re cent myo car di al infarc ti on. 15 Many cli ni ci ans pre fer to use SSRIs for the treat ment of PD-as so ci a ted dep res si on. 16, 17 SSRIs ha ve so me be nign si de ef fects. They do not chan ge cardi ac con duc ti on. 15 Mo re o ver, SSRIs do not block the alp ha-ad re ner gic system or dec re a se the threshold of the se i zu res. 18 So me mem bers of the Parkin son's Study Gro up (PSG) sug gest that SSRIs may wor sen mo tor func ti on in PD. 19 Ho we ver, ma jo rity of the se physi ci ans con ti nu ed using SSRIs, in di cating that this po ten ti al risk may be over co me by the ir be ne fits. In ad di ti on, the se ro to nin syndro me may al so oc cur in pa ti ents ta king SSRIs and se le geli ne con cur rently. 20 Ser tra li ne which is a re la ti vely se lec ti ve SSRI with so me do pa mi ne re-up ta ke in hi bi tor ac ti vity may be par ti cu larly use ful in PD. [20] [21] [22] Be si des these pro per ti es, ser tra li ne has a low po ten ti al for phar ma co ki ne tic in te rac ti ons with ot her drugs and a go od to le ra bi lity pro fi le in el derly pa tients.
In this pros pec ti ve, open-la bel tri al, we ai med to eva lu a te whet her ser tra li ne sho uld ha ve a pla ce in the tre at ment of PD pa ti ents with dep res si on. Thus, in the pre sent study, we exa mi ned the ef fect of this drug on mo od and mo tor im pa ir ments in a gro up of PD pa ti ents with dep res si on.
Torun ve ark. Nöroloji
MATERIAL AND MET HODS
Six te en con se cu ti ve par kin so ni an pa ti ents with a his tory of mo od di sor der ac cor ding to the re sults of struc tu red in ter vi ews and DSM-IV cri te ri a for depres si on 23, 24 we re inc lu ded in this study. The di ag nosis of PD was es tab lis hed by a ne u ro lo gist ba sed on the pre sen ce of at le ast two of three car di nal signs (brady ki ne si a, ri gi dity, and tre mor) plus une qu i vocal res pon se to le vo do pa. Exc lu si on cri te ri a we re as fol lows: (1) sta ges IV and V in Ho ehn and Yahr's sta ging; 25 (2) Axis I di ag no sis ot her than a dep res sive di sor der, inc lu ding any cur rent (wit hin 3 months) di ag no sis of al co hol or drug abu se/de penden ce (with the ex cep ti on of ni co ti ne de pen den ce) (3) pa ti ents ta king an ti dep res si ve me di ca ti ons du ring the pre vi o us three months; (4) ac com pan ying de men ti a as de fi ned by DSM-IV cri te ri a and suppor ted by the Mi ni Men tal Sta te Exa mi na ti on; 26 (5) a his tory of drug to xi city ca u sing hal lu ci na ti ons, deli ri um, or con fu si o nal events; (6) a his tory of stro ke, cra ni o-ce reb ral in jury, or en cep ha li tis; (7) any conco mi tant se ri o us me di cal ill ness.
The pa ti ents we re in for med abo ut the study pro to col and they ga ve the ir in for med con sents. The study pro to col was ap pro ved by the Et hics Com mit te e of the Ko ca e li Uni ver sity Fa culty of Me di ci ne.
Be fo re en roll ment, stan dard la bo ra tory tests and electrocardiogram ECG we re per for med in all pa ti ents. Vi tal func ti ons, blo od pres su re and pul se ra te we re me a su red on each vi sit. Mo tor per forman ce was as ses sed using Uni fi ed Par kin son's Di se a se Ra ting Sca le (UPDRS), and the Ho ehn and Yahr Sta ging Sca le. 27 All pa ti ents had a di ag no sis of ma jor dep res sion (ba sed on DSM-IV cri te ri a), Beck Dep res si on In ven tory (BDI) sco re of ≥9.27 and HAM-D sco re of ≥8.28 BDI and HAM-D we re used as the ma in me a su res of an ti dep res si ve ef fi cacy of ser tra li ne. 8 The Cli ni cal Glo bal As sess ment of Ef fi cacy (CGA -E) was al so used as an ad di ti o nal me a su re of drug ef fi cacy.
The ini ti al do se of ser tra li ne was 25 mg for the first we ek; then it was ad mi nis te red at a do se of 50 mg every mor ning. An ti-par kin so ni an me di ca ti on re ma i ned un mo di fi ed du ring the tri al un less ne cessary. As sess ments we re per for med at ba se li ne and on the 4th and 8th we eks of tre at ment. The sca les we re al ways administered by the sa me in ves ti gator. The pa ti ents we re first as ked whet her they have ex pe ri en ced any ad ver se ef fects, and af ter wards, the oc cu ren ce of a list of symptoms in di ca ting adver se events we re spe ci fi cally qu es ti o ned.
STA TIS TI CAL ANALY SIS
The sta tis ti cal analy sis was per for med using SPSS 11.0 soft wa re. Chan ges in the sco res we re analy sed using Wil co xon rank test. P< 0.05 was set as the sig ni fi can ce le vel.
RE SULTS
The study inc lu ded a to tal of 16 pa ti ents (five males, 11 fe ma les). All pa ti ents comp le ted the study. The me an age of the pa ti ents was 63.56 ± 9.88 years (ran ge, 45-79 ye ars) and me an du ra ti on of PD from the on set of the mo tor im pa ir ment was 101.6 ± 78.2 months (ran ge, 9-312 months). The pa ti ents we re gi ven op ti mal an ti-par kin so ni an drug tre atment du ring the thre e months pri or to the cli ni cal tri al. The pa ti ents we re re ce i ving le vo do pa at a me an do se of 375.0 ± 133.6 mg/day (ran ge, 300-875 mg/day) for a me an of 4.7 ± 6.0 ye ars, along with a de car boxy la se in hi bi tor (six pa ti ents car bido pa, six pa ti ents ben se ra zi de). Eight pa ti ents were ta king se le ge li ne: Five pa ti ents we re re ce i ving 10 mg/day, one pa ti ent 15 mg/day, anot her two pa ti ents 5 mg/day. Fo ur te en pa ti ents we re ta king do pa mi ne ago nists (eight pa ti ents we re ta king bromoc rip ti ne 6.4 ± 4.2 mg/day, and four we re on per go li de tre at ment at a me an do se of 1.06 ± 4.2 mg/day).
Only one pa ti ent had a mo de ra te we a ring-off phe no me non; thus, spe ci al ca re was ta ken to as sess his mo tor sta te du ring his best 'on' pe ri ods. In ot her two pa ti ents, mild pe ak-do se dyski ne si a was ob served at ba se li ne and on day-30, but not on suc ces sive exa mi na ti ons.
The re sults are sum ma ri zed in Tab le 1. The me an ba se li ne HAM-D was 22.06 ± 5.60 and it impro ved to 7.94 ± 2.90 at the end of the study pe riod (8th we eks) (p= 0.000). The me an ba se li ne BDI The me an UPDRS was 45.90 ± 23.10 at ba se line and it sho wed a re duc ti on to 45.40 ± 22.60 at the end of the study (p= 0.502).
Thre e pa ti ents ex pe ri en ced si de ef fects such as in som ni a, ano re xi a, ab do mi nal pa in, in cre a sed pers pi ra ti on, and rest less ness, however de ve lo ped to le ran ce wit hin two we eks. The se pa ti ents we re re ce i ving se le ge li ne along with ser tra li ne. Ho wever, the se ad ver se re ac ti ons we re mild and tran sient. No ne of the pa ti ents ex pe ri en ced se ro to nin syndro me. Du ring the fi nal vi sit, all of the pa tients we re re ce i ving ser tra li ne at a do se of 50 mg/day.
DIS CUS SI ON
The re sults of the pre sent study sho wed that sertra li ne at a do se of 50 mg/day was ef fec ti ve in the tre at ment of dep res si on in PD pa ti ents; and 93.75% (n= 15) and 68.75% of the pa ti ents (n= 11) sho wed 50% or gre a ter im pro ve ment in the sco res of HAM-D and BDI, res pec ti vely.
Cli ni cal glo bal as sess ment of ef fi cacy in di cated that the im pro ve ment ran ged from "go o d" to "ex cel len t" in 12 out of 16 pa ti ents which is in accor dan ce with pre vi o us tri als. 20 The ma jor ad vanta ge of SSRIs is that they are as so ci a ted with fewer se ri o us si de ef fects than TCAs. Among SSRIs, ser tra li ne of fers se ve ral ad van ta ges that may allow gre a ter to le ra bi lity in the el ders. Plas ma le vels of ser tra li ne chan ges with the do se administered and is mostly not af fec ted by the age of the pa ti ent. Furt her mo re, ser tra li ne ca u ses less in hi bi ti on of the P450 IID6 iso enz yme than do es flu o xe ti ne or pa ro xe ti ne, the reby it con veys less po ten ti al for drug-drug phar ma co ki ne tic in te racti ons with ot her me di ca ti ons me ta bo li zed by this enz yme. 20 Alt ho ugh ri go ro us cli ni cal tri al da ta are lac king re gar ding the use of SSRIs and TCAs in the treat ment of dep res si on in PD, the ir use is wi des pre ad in cli ni cal prac ti ce. So me stu di es in di ca te an exacer ba ti on of par kin so nism du ring SSRIs tre at ment in PD pa ti ents with dep res si on whe re as ot her reports sug gest that the se drugs do not af fect mo tor func ti on. Cli ni ci an may be con cer ned that SSRIs may wor sen the pa ti ent's mo tor func ti on by decre a sing do pa mi ne re le a se in nig ros tri a tal path ways; ho we ver, cli ni cal tri al da ta and cli ni cal ex pe ri en ce sup por ting this con si de ra ti on are li mi ted. A da taba se re vi ew of 199 PD pa ti ents tre a ted with an tidep res sant me di ca ti ons fa i led to iden tify any sig ni fi cant dif fe ren ce in the fre qu ency of ex trapyra mi dal symptoms bet we en dif fe rent clas ses of an ti dep res sants. 31 In anot her study with a followup period of six months, 310 PD pa ti ents comp leted the study and wor se ning of tre mor was ob ser ved in so me pa ti ents, however the authors concluded that ac ti ve ma na ge ment of dep res si on with ser tra li ne ap pe ared to ha ve a po si ti ve im pact on par kin so nism. 22 Evi den ce that SSRIs do not wor sen PD co mes from an open-la bel pros pec ti ve study. 32 They com pa red the ef fect of fo ur SSRIs (ci ta lop ram, fluo xe ti ne, flu va xa mi ne and ser tra li ne) on mo tor per for man ce and the inf lu en ce on dep res si on in 65 non-de men ted, non-fluc tu a ting PD pa ti ents with dep res si on. Eva lu a ti on of the ex tra-pyra mi dal and dep res si ve symptoms was per for med by the use of UPDRS, BDI and HAM-D at ba se li ne and on months 1, 3 and 6. UPDRS sco res we re not sig ni ficantly mo di fi ed by add on the rapy with any drug. Dep res si ve symptoms sho wed sig ni fi cant im pro vement with all SSRIs. The se fin dings sug ges ted that SSRIs ame li o ra ted dep res si on wit ho ut sig ni fi cantly wor se ning the ex tra-pyra mi dal symptoms.
In anot her study, ser tra li ne at the sa me do se, in du ced an im pro ve ment in up per limb aki ne si a in dep res sed pa ti ents with PD. 33 Anot her study demons tra ted de te ri o ra ti on of par kin so ni an mo tor symptoms af ter tre at ment with flu o xe ti ne at a dose of 20 mg/day. 34 Two PD pa ti ents with dep res sion in whom par kin so nism was wor se ned by the use of pa ro xe ti ne have al so be en re por ted. 35 A de ta i led ret ros pec ti ve study re por ted an in cre a se in mo tor symptoms in only five of 58 pa ti ents with PD trea ted with SSRIs (two with flu o xe ti ne and three with ser tra li ne). 36 Ex trap yra mi dal re ac ti ons and SSRIs we re revi e wed in a study. 37 The pro po sed hypot he sis for the de ve lop ment of ex trap yra mi dal re ac ti ons by SSRIs inc lu des the in hi bi ti on of the ex trap yra midal do pa mi ner gic ac ti vity by se ro to nin. Ex trap yrami dal re ac ti ons inc lu de dysto ni a, dyski ne si a, akat hi si a, exa cer ba ti on of PD and pos sibly the neu ro lep tic ma lig nant syndro me. The ma jo rity of the symptoms oc cur wit hin the first month of tre atment.
We fo und no sta tis ti cally sig ni fi cant chan ge in UPDRS and H+Y sco res when ser tra li ne was added to treatment. In a study, no chan ge in UPDRS sco res was re por ted in a gro up of 15 pa tients with PD and dep res si on, af ter tre at ment with ser tra li ne 50 mg/day. 20 Anot her study in 54 idi opat hic PD pa ti ents with dep res si ve di sor ders, trea ted with ser tra li ne reported that the re were no sta tis ti cally sig ni fi cant chan ges in UPDRS. 21 A re se arch on the pos sib le in te rac ti on bet ween an ti dep res sants and se le gi li ne re por ted that such an in te rac ti on may re sult in "se ro to nin syndro me". This syndro me is usu ally di ag no sed con si de ring the chan ge in men tal sta tus, the pre sen ce of myoc lonus, swe a ting, hyper ref le xi a, in co or di na ti on and fe ver. In our study, eight pa ti ents we re ta king se legi li ne and no ne of them ex pe ri en ced "se ro to nin syndro me ". A re vi ew of 4568 pa ti ents ta king deprenyl and an an ti dep res sant fo und that less than 1% of the pa ti ents had symptoms of the "se ro to nin syndro me ". 19 Ho we ver, the re is so me evi den ce that the im pa ir ment of mo tor func ti on is mo re com mon in PD pa ti ents with dep res si on ta king SSRIs and deprenyl. 20 Hen ce, the risk of se ro to nin syndro me is mi ni mal and sho uld not prec lu de tre at ment of a pati ent with dep res si on. The con co mi tant use of se lege li ne and SSRIs se ems ge ne rally well to le ra ted. Ca u ti on is ne vert he less ad vi sed when com bi ning an SSRI or a TCA with se le ge li ne. 37 The lack of drug in te rac ti on wo uld be exp la i ned by the exc lusi ve mo no a mi ne o xi da se-A me ta bo lism of se ro tonin, whe re as se le gi li ne is re la ti vely se lec ti ve for mo no a mi ne o xi da se-B in hi bi tor.
In the pre sent study, ser tra li ne was ge ne rally well to le ra ted with mild and tran si ent si de ef fects inc lu ding gas tro in tes ti nal symptoms, in som ni a, ano re xi a, ab do mi nal pa in, in cre a sed pers pi ra ti on, and rest less ness.
In conc lu si on, the pre sent study sug gests that ser tra li ne at a do se of 50 mg/day im pro ves dep ressi on wit ho ut exa cer ba ting the par kin so ni an symptoms. Ser tra li ne was ge ne rally well to le ra ted, si de ef fects we re mild and tran si ent and no ne of the pati ents ex pe ri en ced a "se ro to nin syndro me ". The limi ta ti ons of this study we re small samp le si ze and lack of a pla ce bo-con trol led desing. We suppose that pla ce bo-con trol led tri als on lar ger po pu la ti ons are re qu i red to con firm both the ef fi cacy of ser trali ne and its ef fect on par kin so nism in PD pa ti ents with dep res si on.
